IL-9 Producing Tumor-Infiltrating Lymphocytes and Treg Subsets Drive Immune Escape of Tumor Cells in Non-Small Cell Lung Cancer
Copyright © 2022 Heim, Yang, Tausche, Hohenberger, Chiriac, Koelle, Geppert, Kachler, Miksch, Graser, Friedrich, Kharwadkar, Rieker, Trufa, Sirbu, Neurath, Kaplan and Finotto..
Although lung cancer is the leading cause of cancer deaths worldwide, the mechanisms how lung cancer cells evade the immune system remain incompletely understood. Here, we discovered IL-9-dependent signaling mechanisms that drive immune evasion in non-small cell lung cancer (NSCLC). We found increased IL-9 and IL-21 production by T cells in the tumoral region of the lung of patients with NSCLC, suggesting the presence of Th9 cells in the lung tumor microenvironment. Moreover, we noted IL-9 producing Tregs in NSCLC. IL-9 target cells in NSCLC consisted of IL-9R+ tumor cells and tumor-infiltrating lymphocytes. In two murine experimental models of NSCLC, and in vitro, IL-9 prevented cell death and controlled growth of lung adenocarcinoma cells. Targeted deletion of IL-9 resulted in successful lung tumor rejection in vivo associated with an induction of IL-21 and reduction of Treg cells. Finally, anti-IL-9 antibody immunotherapy resulted in suppression of tumor development even in established experimental NSCLC and was associated with reduced IL-10 production in the lung. In conclusion, our findings indicate that IL-9 drives immune escape of lung tumor cells via effects on tumor cell survival and tumor infiltrating T cells. Thus, strategies blocking IL-9 emerge as a new approach for clinical therapy of lung cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022) vom: 23., Seite 859738 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Heim, Lisanne [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
IL-9 |
|---|
| Anmerkungen: |
Date Completed 09.05.2022 Date Revised 05.05.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.859738 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340435275 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340435275 | ||
| 003 | DE-627 | ||
| 005 | 20231226204613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.859738 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340435275 | ||
| 035 | |a (NLM)35514957 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Heim, Lisanne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IL-9 Producing Tumor-Infiltrating Lymphocytes and Treg Subsets Drive Immune Escape of Tumor Cells in Non-Small Cell Lung Cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.05.2022 | ||
| 500 | |a Date Revised 05.05.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Heim, Yang, Tausche, Hohenberger, Chiriac, Koelle, Geppert, Kachler, Miksch, Graser, Friedrich, Kharwadkar, Rieker, Trufa, Sirbu, Neurath, Kaplan and Finotto. | ||
| 520 | |a Although lung cancer is the leading cause of cancer deaths worldwide, the mechanisms how lung cancer cells evade the immune system remain incompletely understood. Here, we discovered IL-9-dependent signaling mechanisms that drive immune evasion in non-small cell lung cancer (NSCLC). We found increased IL-9 and IL-21 production by T cells in the tumoral region of the lung of patients with NSCLC, suggesting the presence of Th9 cells in the lung tumor microenvironment. Moreover, we noted IL-9 producing Tregs in NSCLC. IL-9 target cells in NSCLC consisted of IL-9R+ tumor cells and tumor-infiltrating lymphocytes. In two murine experimental models of NSCLC, and in vitro, IL-9 prevented cell death and controlled growth of lung adenocarcinoma cells. Targeted deletion of IL-9 resulted in successful lung tumor rejection in vivo associated with an induction of IL-21 and reduction of Treg cells. Finally, anti-IL-9 antibody immunotherapy resulted in suppression of tumor development even in established experimental NSCLC and was associated with reduced IL-10 production in the lung. In conclusion, our findings indicate that IL-9 drives immune escape of lung tumor cells via effects on tumor cell survival and tumor infiltrating T cells. Thus, strategies blocking IL-9 emerge as a new approach for clinical therapy of lung cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a IL-9 | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a TIL | |
| 650 | 4 | |a immune escape | |
| 650 | 4 | |a tumor immunotherapy | |
| 650 | 7 | |a Interleukin-9 |2 NLM | |
| 700 | 1 | |a Yang, Zuqin |e verfasserin |4 aut | |
| 700 | 1 | |a Tausche, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Hohenberger, Katja |e verfasserin |4 aut | |
| 700 | 1 | |a Chiriac, Mircea T |e verfasserin |4 aut | |
| 700 | 1 | |a Koelle, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Geppert, Carol-Immanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Kachler, Katerina |e verfasserin |4 aut | |
| 700 | 1 | |a Miksch, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Graser, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Friedrich, Juliane |e verfasserin |4 aut | |
| 700 | 1 | |a Kharwadkar, Rakshin |e verfasserin |4 aut | |
| 700 | 1 | |a Rieker, Ralf J |e verfasserin |4 aut | |
| 700 | 1 | |a Trufa, Denis I |e verfasserin |4 aut | |
| 700 | 1 | |a Sirbu, Horia |e verfasserin |4 aut | |
| 700 | 1 | |a Neurath, Markus F |e verfasserin |4 aut | |
| 700 | 1 | |a Kaplan, Mark H |e verfasserin |4 aut | |
| 700 | 1 | |a Finotto, Susetta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022) vom: 23., Seite 859738 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g day:23 |g pages:859738 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.859738 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |b 23 |h 859738 | ||